A Phase I Study Of Lxh254 In Patients (Pts) With Advanced Solid Tumors Harboring Mapk Pathway Alterations.

Filip Janku,Gopa Iyer,Noboru Yamamoto,Yung-Jue Bang,Elena Elez,Maja J.A. de Jonge,Harry J.M. Groen,Frederik Marme,Kathrin Gollmer,Annie St-Pierre, Maritza Melendez,Anna Mais,Heidi Nauwelaerts,Uz Stammberger,Reinhard Dummer

JOURNAL OF CLINICAL ONCOLOGY（2018）

引用 15|浏览32

暂无评分

摘要

2586Background: CRAF is a key mediator of oncogenic mitogen-activated protein kinase (MAPK) pathway reactivation following MEK or BRAF inhibition. LXH254 is a BRAF and CRAF inhibitor with antitumor...

查看译文

关键词

mapk pathway alterations,lxh254,advanced solid tumors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要